$DRIO
DarioHealth Corp.

2021 Q4 Form 10-Q Financial Statement

#000155837021016008 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $6.028M $5.629M $2.042M
YoY Change 189.81% 175.66% 9.2%
Cost Of Revenue $5.480M $3.097M $1.493M
YoY Change 258.17% 107.43% 49.3%
Gross Profit $548.0K $826.0K $549.0K
YoY Change -0.36% 50.46% -36.9%
Gross Profit Margin 9.09% 14.67% 26.89%
Selling, General & Admin $16.90M $17.82M $6.200M
YoY Change 106.31% 187.4% 120.64%
% of Gross Profit 3083.39% 2157.26% 1129.33%
Research & Development $5.316M $5.506M $954.0K
YoY Change 274.37% 477.15% 10.93%
% of Gross Profit 970.07% 666.59% 173.77%
Depreciation & Amortization $719.0K $1.359M $50.00K
YoY Change 1338.0% 2618.0% 0.0%
% of Gross Profit 131.2% 164.53% 9.11%
Operating Expenses $22.21M $23.33M $7.151M
YoY Change 131.14% 226.18% 94.85%
Operating Profit -$21.67M -$22.50M -$6.602M
YoY Change 139.13% 240.79% 135.79%
Interest Expense $135.0K $59.00K $60.00K
YoY Change 92.86% -1.67% -700.0%
% of Operating Profit
Other Income/Expense, Net -$24.00K $55.00K $52.00K
YoY Change 140.0% 5.77%
Pretax Income -$21.55M -$22.44M -$6.550M
YoY Change 139.49% 242.66% 133.1%
Income Tax $32.00K
% Of Pretax Income
Net Earnings -$21.59M -$22.44M -$6.550M
YoY Change 139.84% 242.66% 133.1%
Net Earnings / Revenue -358.1% -398.72% -320.76%
Basic Earnings Per Share -$1.18 -$0.71
Diluted Earnings Per Share -$1.215M -$1.18 -$0.71
COMMON SHARES
Basic Shares Outstanding 16.58M 16.47M 7.328M
Diluted Shares Outstanding 16.47M 7.328M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.00M $51.58M $37.10M
YoY Change 25.0% 39.04% 672.92%
Cash & Equivalents $35.81M $51.33M $36.91M
Short-Term Investments $192.0K $251.0K $200.0K
Other Short-Term Assets $76.00K
YoY Change -5.0%
Inventory $6.228M $4.058M $1.600M
Prepaid Expenses
Receivables $1.310M $2.106M $500.0K
Other Receivables $2.067M $1.481M $700.0K
Total Short-Term Assets $45.61M $59.23M $39.80M
YoY Change 33.63% 48.81% 452.78%
LONG-TERM ASSETS
Property, Plant & Equipment $702.0K $713.0K $1.100M
YoY Change 21.88% -35.18% -21.43%
Goodwill $41.64M $39.40M
YoY Change
Intangibles $12.46M $17.41M
YoY Change
Long-Term Investments
YoY Change
Other Assets $77.00K $77.00K $200.0K
YoY Change -61.5% -61.5% 100.0%
Total Long-Term Assets $55.17M $57.96M $1.300M
YoY Change 4213.21% 4358.38% -7.14%
TOTAL ASSETS
Total Short-Term Assets $45.61M $59.23M $39.80M
Total Long-Term Assets $55.17M $57.96M $1.300M
Total Assets $100.8M $117.2M $41.10M
YoY Change 184.61% 185.12% 377.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.109M $3.990M $2.000M
YoY Change 104.36% 99.5% 42.86%
Accrued Expenses $4.398M $293.0K $300.0K
YoY Change 399.77% -2.33% 0.0%
Deferred Revenue $1.195M $1.213M
YoY Change -2.37%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.20M $12.68M $5.900M
YoY Change 116.11% 114.93% 40.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $846.0K $66.00K $300.0K
YoY Change 323.0% -78.0% -40.0%
Total Long-Term Liabilities $21.00K $66.00K $300.0K
YoY Change -90.54% -78.0% -40.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.20M $12.68M $5.900M
Total Long-Term Liabilities $21.00K $66.00K $300.0K
Total Liabilities $15.22M $12.75M $6.100M
YoY Change 109.79% 108.97% 29.79%
SHAREHOLDERS EQUITY
Retained Earnings -$222.0M -$199.9M
YoY Change 54.99%
Common Stock $2.000K $0.00 $28.59M
YoY Change -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.55M $104.4M $35.03M
YoY Change
Total Liabilities & Shareholders Equity $100.8M $117.2M $41.10M
YoY Change 184.61% 185.12% 377.91%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$21.59M -$22.44M -$6.550M
YoY Change 139.84% 242.66% 133.1%
Depreciation, Depletion And Amortization $719.0K $1.359M $50.00K
YoY Change 1338.0% 2618.0% 0.0%
Cash From Operating Activities -$15.14M -$12.44M -$3.800M
YoY Change 123.91% 227.24% 12.43%
INVESTING ACTIVITIES
Capital Expenditures -$68.00K -$96.00K -$30.00K
YoY Change 36.0% 220.0% 200.0%
Acquisitions
YoY Change
Other Investing Activities -$376.0K -$1.000K $0.00
YoY Change -74.93% -100.0%
Cash From Investing Activities -$444.0K -$97.00K -$30.00K
YoY Change -71.35% 223.33% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 27.55M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -15.14M -12.44M -3.800M
Cash From Investing Activities -444.0K -97.00K -30.00K
Cash From Financing Activities 0.000 0.000 27.55M
Net Change In Cash -15.58M -12.53M 23.72M
YoY Change 87.48% -152.83% -795.6%
FREE CASH FLOW
Cash From Operating Activities -$15.14M -$12.44M -$3.800M
Capital Expenditures -$68.00K -$96.00K -$30.00K
Free Cash Flow -$15.07M -$12.34M -$3.770M
YoY Change 124.56% 227.29% 11.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.18
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.95
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16473449
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7328420
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16202541
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4856115
dei Entity Central Index Key
EntityCentralIndexKey
0001533998
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8119493
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16509344
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
15823
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
12097
dei Security Exchange Name
SecurityExchangeName
NASDAQ
us-gaap Revenue Practical Expedient Remaining Performance Obligation
RevenuePracticalExpedientRemainingPerformanceObligation
true
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37704
dei Entity Registrant Name
EntityRegistrantName
DarioHealth Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2973162
dei Entity Address Address Line1
EntityAddressAddressLine1
142 W. 57th St., 8th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
dei City Area Code
CityAreaCode
646
dei Local Phone Number
LocalPhoneNumber
665-4667
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
DRIO
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
124000
CY2021Q3 us-gaap Inventory Net
InventoryNet
4058000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2293000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1481000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2934000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5629000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2042000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14485000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16575633
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51331000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28590000
CY2021Q3 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
251000
CY2020Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
187000
CY2021Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
2106000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Assets Current
AssetsCurrent
59227000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
34128000
CY2021Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
20000
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
20000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
361000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
498000
CY2021Q3 drio Long Term Assets Noncurrent
LongTermAssetsNoncurrent
57000
CY2020Q4 drio Long Term Assets Noncurrent
LongTermAssetsNoncurrent
185000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
713000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
576000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
17409000
CY2021Q3 us-gaap Goodwill
Goodwill
39399000
CY2021Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
57959000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
1279000
CY2021Q3 us-gaap Assets
Assets
117186000
CY2020Q4 us-gaap Assets
Assets
35407000
CY2021Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
3990000
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2480000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1213000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1224000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
293000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
310000
CY2021Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
7185000
CY2020Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
3020000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12681000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7034000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
66000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
222000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16509344
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8119493
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
12097
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
15823
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
304382000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
171399000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199943000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143248000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
104439000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28151000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117186000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35407000
us-gaap Operating Expenses
OperatingExpenses
22803000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22499000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
52000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6602000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54829000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5496000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3097000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20839000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
55000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1493000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7746000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3532000
CY2021Q3 drio Amortization Of Acquired Technology And Inventory
AmortizationOfAcquiredTechnologyAndInventory
1706000
drio Amortization Of Acquired Technology And Inventory
AmortizationOfAcquiredTechnologyAndInventory
3324000
CY2021Q3 us-gaap Gross Profit
GrossProfit
826000
CY2020Q3 us-gaap Gross Profit
GrossProfit
549000
us-gaap Gross Profit
GrossProfit
3415000
us-gaap Gross Profit
GrossProfit
1964000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5506000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
954000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11903000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3010000
CY2021Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
10696000
CY2020Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3635000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
27476000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
10334000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7123000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2562000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18865000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9459000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
23325000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
7151000
us-gaap Operating Expenses
OperatingExpenses
58244000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-346000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
391000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22444000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6550000
us-gaap Net Income Loss
NetIncomeLoss
-55175000
us-gaap Net Income Loss
NetIncomeLoss
-20448000
CY2021Q3 drio Deemed Dividend
DeemedDividend
-488000
CY2020Q3 drio Deemed Dividend
DeemedDividend
-930000
drio Deemed Dividend
DeemedDividend
-1520000
drio Deemed Dividend
DeemedDividend
-2991000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22932000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7480000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-56695000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23439000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.18
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.95
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16473449
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7328420
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16202541
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4856115
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28151000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
72000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
201000
CY2021Q1 drio Warrants Issued During Period Exercise Of Warrants Value
WarrantsIssuedDuringPeriodExerciseOfWarrantsValue
633000
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1484000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
846000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2036000
CY2021Q1 drio Stock Issued During Period Value Common Stock
StockIssuedDuringPeriodValueCommonStock
64877000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14966000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
112267000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
889000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1951000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2595000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17765000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
118113000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
34000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
303000
CY2021Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1705000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2121000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4607000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22444000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
104439000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
18894000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
274000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
4076000
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
360000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1131000
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
583000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9892000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
15426000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
141000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
17000
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
180000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
150000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
318000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4006000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
12226000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
193000
CY2020Q3 drio Warrants Issued During Period Exercise Of Repriced Warrants Value
WarrantsIssuedDuringPeriodExerciseOfRepricedWarrantsValue
1088000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
670000
CY2020Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
531000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
90000
CY2020Q3 drio Stock Issued During Period Value Common Stock
StockIssuedDuringPeriodValueCommonStock
26460000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
326000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6550000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
35034000
us-gaap Net Income Loss
NetIncomeLoss
-55175000
us-gaap Net Income Loss
NetIncomeLoss
-20448000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
18670000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
8988000
us-gaap Depreciation
Depreciation
202000
us-gaap Depreciation
Depreciation
140000
drio Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-137000
drio Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-224000
drio Amortization Of Inventory Set Up
AmortizationOfInventorySetUp
985000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2396000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1125000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-129000
drio Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets
IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets
221000
drio Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets
IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets
-338000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-96000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
158000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
343000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1368000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
311000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-139000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
62000
drio Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-173000
drio Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-229000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35273000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10976000
drio Payments For Proceeds From Acquire Leases Held For Investment
PaymentsForProceedsFromAcquireLeasesHeldForInvestment
2000
drio Payments For Proceeds From Acquire Leases Held For Investment
PaymentsForProceedsFromAcquireLeasesHeldForInvestment
4000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
193000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
69000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
5023000
drio Payments For Loans Acquired During Business Combination
PaymentsForLoansAcquiredDuringBusinessCombination
3016000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
544000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7690000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64877000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27548000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
633000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
256000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65766000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27548000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
22803000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
16499000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28725000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20535000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51528000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37034000
drio Liability Business Acquisition
LiabilityBusinessAcquisition
256000
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Operating Income Loss
OperatingIncomeLoss
-54829000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35273000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51331000
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51331000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36907000
CY2021Q3 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
197000
CY2020Q3 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
127000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51528000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37034000
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 3: -   UNAUDITED INTERIM FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">The accompanying unaudited interim consolidated financial statements as of September 30, 2021, have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the Company’s consolidated financial position as of September 30, 2021, and the Company’s consolidated results of operations and the Company’s consolidated cash flows for the nine months ended September 30, 2021. Results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 54pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p>
CY2021Q1 drio Business Combination Liability Consideration Restricted Common Stock Held In Escrow For Holdback Service Period
BusinessCombinationLiabilityConsiderationRestrictedCommonStockHeldInEscrowForHoldbackServicePeriod
113576
CY2021Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1117000
CY2020Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
377000
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2941000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1916000
CY2021Q3 us-gaap Inventory Net
InventoryNet
4058000
CY2020Q4 us-gaap Inventory Net
InventoryNet
2293000
us-gaap Inventory Write Down
InventoryWriteDown
91000
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
99000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5629000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2042000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14485000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5496000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1224000
CY2021Q3 drio New Performance Obligations
NewPerformanceObligations
2617000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-2628000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1213000
CY2021Q3 drio Class Of Warrant Or Right Compensation Expense
ClassOfWarrantOrRightCompensationExpense
273000
CY2021Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
219992
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
633000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40545
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
256000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
973575
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.56
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y11M26D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5510000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
905573
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
20.28
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40545
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
46900
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
49.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
52195
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.93
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1739508
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.40
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M13D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4518000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1647018
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.51
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y10M2D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4324000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
372630
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
32.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7M24D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4070000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-346000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
391000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
28459000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M12D
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18670000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8988000
drio Bank Charges
BankCharges
60000
drio Bank Charges
BankCharges
42000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-322000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
382000
us-gaap Investment Income Interest
InvestmentIncomeInterest
36000
us-gaap Investment Income Interest
InvestmentIncomeInterest
51000

Files In Submission

Name View Source Status
0001558370-21-016008-index-headers.html Edgar Link pending
0001558370-21-016008-index.html Edgar Link pending
0001558370-21-016008.txt Edgar Link pending
0001558370-21-016008-xbrl.zip Edgar Link pending
drio-20210930.xsd Edgar Link pending
drio-20210930x10q.htm Edgar Link pending
drio-20210930x10q_htm.xml Edgar Link completed
drio-20210930xex31d1.htm Edgar Link pending
drio-20210930xex31d2.htm Edgar Link pending
drio-20210930xex32d1.htm Edgar Link pending
drio-20210930xex32d2.htm Edgar Link pending
drio-20210930_cal.xml Edgar Link unprocessable
drio-20210930_def.xml Edgar Link unprocessable
drio-20210930_lab.xml Edgar Link unprocessable
drio-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending